Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Intarcia Therapeutics (Hayward, CA), a clinical stage medical device company focused on developing a subcutaneous device to continuously deliver diabetes therapeutic exenatide, closed a $160M Series C financing, in addition to a $50M debt financing, totaling $210M for the round. Participants include New Enterprise Associates, New Leaf Venture Partners, Venrock, The Baupost Group, and Farallon […]

Cibiem (New York, NY), a development-stage medical device company focused on sympathetic nervous system-mediated diseases, closed a $10M Series A financing. Participants include SV Life Sciences and Third Rock Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account […]

GlySure (United Kingdom) a clinical-stage medical device company focused on a intravascular, optical fluorescence-based sensor for continuous blood glucose monitoring systems, closed a $10.9M Series C financing. Participants include Morningside Venture, Amadeus Capital Partners, Chester Investments and Delta Partners.

C8 MediSensors (San Jose, CA) a clinical-stage medical device company focused on non-invasive continuous glucose monitors, closed a $24M Series E financing. Participants have included GE Healthymagination Fund.

Sensors for Medicine and Science (Germantown, MD) a commercial-stage device company focused on implantable, long- term continuous glucose monitoring, closed a $54.1M million in Series D financing. Participants include Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a $12M Series D financing, bringing the total round to $76M. Participants include Accuitive Medical Ventures, Investor Growth Capital, Thomas McNerney, Venrock, Versant Ventures and U.S. Venture Partners. Thanx for your patience as we catch-up.

Valeritas (Bridgewater, NJ) a commercial-stage developer of a disposable insulin delivery device, closed a $150M Series C financing. Participants include Welsh, Carson, Anderson & Stowe, MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, Onset Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.

Tandem Diabetes Care (San Diego, CA) a development-stage medical device company focused on insulin pump technology, closed a $30.8M Series C financing, bringing the total round to $52.3M. Participants include HLM Venture Partners, Domain Associates, TPG Biotech, Delphi Ventures and Kearny Venture Partners.

CeQur (Switzerland) a development-stage device company focused on a wearable insulin infuser for the continuous subcutaneous delivery of insulin for Type II diabetes, closed a $29.6M Series A financing. Participants include BMC Ventures, Endeavour Vision, Schroders and Venture Incubator.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a Series D financing. Participants include Venrock, Emergent Medical Partners, Investor Growth Capital, Thomas McNerney and Partners, U.S. Venture Partners and Versant Ventures.

Tethys Bioscience (Emeryville, CA) a commercial-stage diagnostics company focused on type II diabetes risk assessment through the measurement of multiple biomarkers, closed a $25M Series D financing. Participants include Capital AG, Wasatch Advisors, Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

MetaCure (Orangeburg, NY) a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation, closed a $20M Series B financing. Participants include the Morningside Group.

« Previous Entries  Next Page »

to top of page...